Skip to main content

Table 2 Model transition probabilities by GOLD states

From: Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden

Usual care

First cycle

Subsequent treatment cycles

TO

TO

GOLD II

GOLD III

GOLD IV

GOLD II

GOLD III

GOLD IV

FROM

 GOLD II

0.86

0.13

0.01

0.91

0.09

0.00

 GOLD III

0.13

0.81

0.06

0.08

0.88

0.04

 GOLD IV

0.02

0.22

0.76

0.00

0.13

0.87

Tiotropium/glycopyrronium

First cycle

Subsequent treatment cycles

TO

TO

GOLD II

GOLD III

GOLD IV

GOLD II

GOLD III

GOLD IV

FROM

 GOLD II

0.92

0.08

0.00

0.92

0.08

0.00

 GOLD III

0.17

0.80

0.03

0.08

0.88

0.04

 GOLD IV

0.03

0.28

0.69

0.00

0.12

0.88

  1. Source: [28] (derived from [17]). For tiotropium and glycopyrronium cohorts, usual care probabilities were assumed to hold when off treatment. Probabilities have been recalculated to reflect three month probabilities. Death has been excluded, as this model carries separate mortality rates derived for a Swedish population